<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>949</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>1698871</PubmedId>
            <Abstract>The site-1 determinant of the hemagglutinin molecule of influenza virus (A/PR/8/34) is one of several immunodominant sites in the BALB/c Th cell response to Ha. A synthetic peptide comprising this T cell site (HA110-120), a panel of analogs containing single substitutions in this determinant, and homologs truncated at the amino- or carboxyl-terminal were used to examine the fine specificities of 15 T cells specific for site-1 in the context of I-Ed. The results indicate that every residue within the minimal determinant plays a role in the T cell recognition process, as single substitutions at any of these positions affected the ability of the peptide to stimulate at least some site 1-specific T cells. For the majority of the residues examined, substitutions had dissimilar effects on distinct T cells, indicating that the substituted residues were affecting recognition in a receptor-specific manner. Each of the 15 T cells examined had a distinct fine specificity pattern, suggesting that the BALB/c T cell repertoire for this site is likely to exceed 100 distinct clonotypes.</Abstract>
            <ArticleYear>1990</ArticleYear>
            <ArticlePages>3087-94</ArticlePages>
            <ArticleTitle>A large degree of functional diversity exists among helper T cells specific for the same antigenic site of influenza hemagglutinin.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Haberman</LastName>
                    <ForeName>A M</ForeName>
                </Author>
                <Author>
                    <LastName>Moller</LastName>
                    <ForeName>C</ForeName>
                </Author>
                <Author>
                    <LastName>McCreedy</LastName>
                    <ForeName>D</ForeName>
                </Author>
                <Author>
                    <LastName>Gerhard</LastName>
                    <ForeName>W U</ForeName>
                </Author>
            </Authors>
            <Affiliations>Wistar Institute of Anatomy and Biology, Philadelphia, PA 19104.</Affiliations>
            <ArticleChemicalList>Epitopes;Hemagglutinins, Viral;Histocompatibility Antigens Class II;I-E-antigen;Oligopeptides</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Epitopes; Hemagglutinins, Viral(immunology); Histocompatibility Antigens Class II(immunology); Hybridomas(immunology); Influenza A virus(immunology); Lymphocyte Activation; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Oligopeptides(chemical synthesis; immunology); Structure-Activity Relationship; T-Lymphocytes, Helper-Inducer(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>145</Volume>
                <Issue>9</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HA 110-120</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SFERFEIFPKE</LinearSequence>
                        <StartingPosition>127</StartingPosition>
                        <EndingPosition>137</EndingPosition>
                        <SourceMolecule>
                            <IedbAccession>SRC133</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table I</LocationOfData>
                <EpitopeId>57751</EpitopeId>
                <ReferenceStartingPosition>110</ReferenceStartingPosition>
                <ReferenceEndingPosition>120</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>I-Ed restricted epitope shown to stimulate 15 T cell clones, with a minimal epitope identified as 111-119 for the majority of those cell lines. Non-conservative substitution of those residues shows that aa F111, I116 and K119 are required for stimulation. This effect is not unequivocally attributed to a lack of recognition by the T cell clone or to the inability of this mutated peptides to bind I-Ed MHC molecule. Swiss-prot entry and positions correspond to the hemagglutinin precursor.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table III</LocationOfData>
                        <TCellId>11412</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SFERFEIFPKE</LinearSequence>
                                            <StartingPosition>127</StartingPosition>
                                            <EndingPosition>137</EndingPosition>
                                            <SourceMolecule>
                                                <IedbAccession>SRC133</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HA 110-120</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 30 micrograms of peptide, either mutant or WT.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Lymph node cells</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SFERFEIFPKE</LinearSequence>
                                            <StartingPosition>127</StartingPosition>
                                            <EndingPosition>137</EndingPosition>
                                            <SourceMolecule>
                                                <IedbAccession>SRC133</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>SIN were harvested 7 -10 days after immunization,  and restimulated in vitro with irradiated splenocytes and the mutant form of peptide used in the immunization or with the parental form.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>116</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 110-120</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SFERFEIFPKE</LinearSequence>
                                        <StartingPosition>127</StartingPosition>
                                        <EndingPosition>137</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC133</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>69</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunization with F111 to Glu and K 119 to Glu mutant peptides did not induce T cell responses against themselves or the unmutated parental peptide. However, I116 to Glu mutant peptide immunization was able to elicit a T cell proliferative response when stimulated with parental or mutant peptide, implying this mutant retains the capability of associating with the MHC molecule.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Tables I  and II</LocationOfData>
                        <TCellId>11410</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 1000 HAU</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Lymph node cells</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SFERFEIFPKE</LinearSequence>
                                            <StartingPosition>127</StartingPosition>
                                            <EndingPosition>137</EndingPosition>
                                            <SourceMolecule>
                                                <IedbAccession>SRC133</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>6 T cell cones were generated with in vitro stimulation with epitope of source species primed lymphocytes, followed by fusion with thymoma cell line BW5147. Other T cell clones were generated identically except that in vitro stimulation was done with source protein or source species, and 1 T cell clone was generated from a peptide immunized mice by in vitro stimulation with peptide prior to fusion.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Lymph Node</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>116</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>HA 110-120</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SFERFEIFPKE</LinearSequence>
                                        <StartingPosition>127</StartingPosition>
                                        <EndingPosition>137</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC133</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>221</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Peptides truncated at  F111 or K119 result in lower levels of IL-3 secretion. The potency of peptide 111-119 is comparable to that of peptide 110-120 for 10 out of 15 T cell lines. Mutation of residues F111, I116 and K119 abolishes reactivity for all T cells. Other positions are less consistent in their effect, with some lines affeceted while others are not. The lack of any identical reactivity profile among the 15 cell lines to peptide mutations imply that the diveristy of the T cell response to this epitope is large.  T cell clones and irradiated splenocytes were cultured for 48 hours in the presence of peptide. Supernatants were assessed for IL-3 by proliferation and viability of the IL-3 dependent cell line DA-1.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

